Back to top
more

Globus Medical (GMED)

(Delayed Data from NYSE)

$56.22 USD

56.22
1,419,026

-1.62 (-2.80%)

Updated Sep 17, 2025 04:00 PM ET

After-Market: $56.22 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.64%
2Buy17.83%
3Hold9.69%
4Sell5.29%
5Strong Sell2.54%
S&P50011.29%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (93 out of 245)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Globus Medical (GMED) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

Globus Medical (GMED) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

OrthoPediatrics (KIDS) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

OrthoPediatrics (KIDS) delivered earnings and revenue surprises of 73.68% and 4.09%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

3 Reasons to Retain Nevro (NVRO) Stock in Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about Nevro (NVRO), owing to its strength in the global SCS market.

Zacks Equity Research

Charles River's (CRL) New Launch to Boost Gene Therapy Workflow

by Zacks Equity Research

Charles River's (CRL) latest product offering is expected to streamline the pathway to GMP AAV vector manufacturing without significant process development.

Zacks Equity Research

AngioDynamics (ANGO) Q1 Earnings, Revenues Lag Estimates

by Zacks Equity Research

AngioDynamics (ANGO) registers strong revenue growth in the Med Tech business in first-quarter fiscal 2023.

Zacks Equity Research

Here's Why Investors Should Retain Globus Medical (GMED) For Now

by Zacks Equity Research

Investors are optimistic about Globus Medical's (GMED) better-than-expected results and new product introductions.

Zacks Equity Research

Globus Medical (GMED) Gains Market Share, Cost Woes Stay

by Zacks Equity Research

Globus Medical (GMED) U.S. sales increase, driven by competitive rep conversions and robotic pull-through.

Zacks Equity Research

Globus Medical (GMED) Q2 Earnings Beat, Gross Margin Dips

by Zacks Equity Research

Globus Medical's (GMED) Musculoskeletal Solutions products generate solid revenues on growth in spine and trauma implant portfolios.

Zacks Equity Research

Globus Medical (GMED) Q2 Earnings and Revenues Top Estimates

by Zacks Equity Research

Globus Medical (GMED) delivered earnings and revenue surprises of 3.70% and 2%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

AxoGen (AXGN) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

AxoGen (AXGN) delivered earnings and revenue surprises of 60% and 5.04%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

ViewRay (VRAY) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

ViewRay (VRAY) delivered earnings and revenue surprises of 0% and 13.19%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Analysts Estimate Orthofix (OFIX) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Orthofix (OFIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Analysts Estimate Globus Medical (GMED) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Globus Medical (GMED) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

AngioDynamics (ANGO) Q4 Earnings Match Estimates

by Zacks Equity Research

AngioDynamics (ANGO) delivered earnings and revenue surprises of 0% and 5.27%, respectively, for the quarter ended May 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Equity Research

Why Is Globus Medical (GMED) Up 1.7% Since Last Earnings Report?

by Zacks Equity Research

Globus Medical (GMED) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Here's Why Investors Should Retain Globus Medical (GMED) Now

by Zacks Equity Research

Globus Medical's (GMED) strong international growth and meaningful product launches raise investors' optimism.

Zacks Equity Research

Globus Medical (GMED) Completes First Cases With Excelsius3D

by Zacks Equity Research

Globus Medical's (GMED) Excelsius3D, when combined with ExcelsiusGPS, facilitates greater implant placement accuracy, lowers radiation exposure and reduces operative times.

Zacks Equity Research

Globus Medical (GMED) Q1 Earnings Miss Estimates, Margins Dip

by Zacks Equity Research

According to Globus Medical (GMED), its Q1 results reflect modest revenue growth against a difficult prior-year comparison, coupled with COVID-related revenue impacts in key countries.

Zacks Equity Research

Globus Medical (GMED) Misses Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Globus Medical (GMED) delivered earnings and revenue surprises of -8.70% and 1.22%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Inogen (INGN) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Inogen (INGN) delivered earnings and revenue surprises of 20.83% and 5.09%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Analysts Estimate Globus Medical (GMED) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Globus Medical (GMED) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Globus Medical (GMED) Stock Fell on Preliminary Q1 Sales Results

by Zacks Equity Research

Globus Medical's (GMED) Q1 preliminary sales results reflect an increase in procedural volumes along with growth in Enabling Technologies business.

Riya Anand headshot

Orthopedics Device Space Gaining Prominence: 3 Stocks in Focus

by Riya Anand

Stocks like Orthofix Medical Inc. (OFIX), Stryker Corporation (SYK) and NuVasive, Inc. (NUVA) are likely to gain enormously from developments in the orthopedic space.

Zacks Equity Research

Here's Why You Should Retain Globus Medical (GMED) Stock Now

by Zacks Equity Research

Investors are optimistic about Globus Medical's (GMED) better-than-expected results and strength in the U.S. Spine business.